Accession Number : ADB119275
Title : Transdermal Drug Delivery System. Stage 1. Volume 2.
Descriptive Note : Final rept. 15 Aug 85-14 Oct 87,
Corporate Author : RIKER LABS INC ST PAUL MN
Personal Author(s) : Westfall, Maria J. ; Mitra, Amit K. ; Kolars, C. A. ; Dahms, J. K. ; Rohde, K. A.
Report Date : 30 DEC 1987
Pagination or Media Count : 168
Abstract : The US Army requested proposals for a four-stage program aimed at the development, optimization, and production of a transdermal drug delivery system (TDDS) for the drug, pyridostigmine bromide. Stage I of the work had the objective to explore alternative TDDs concepts and proposed the simultaneous exploration of three design approaches; the drug incorporated into 3M proprietary hypoallergenic adhesives, the drug incorporated into 3M proprietary hypoallergenic adhesives, the drug incorporated into a gel diffusion matrix, and the drug delivered from an iontophoretic system. During a five-month feasibility study, Medtronic, Inc. provided and tested an iontophoretic system. Preliminary in vitro and in vivo results indicated that pyridostigmine bromide from nonpolar adhesive based systems was very low, and polar adhesive based systems did not have acceptable physical properties for a pressure sensitive adhesive. A wide range of components were incorporated into polyvinyl alcohol based gel diffusion matrices. The formulations were screened both in vitro and in vivo and they met initial delivery requirements.
Descriptors : *CHOLINESTERASE INHIBITORS, *PHARMACOLOGY, ADHESIVES, BROMIDES, CARBAMATES, DELIVERY, DRUGS, HYDROXYL RADICALS, IN VITRO ANALYSIS, IN VIVO ANALYSIS, METHYL RADICALS, OPTIMIZATION, PHYSICAL PROPERTIES, POLARIZATION, PRODUCTION, PYRIDINES, REQUIREMENTS, SYNCHRONISM, FORMULATIONS(CHEMISTRY), SKIN(ANATOMY), BIOLOGICAL ABSORPTION, GELS, DIFFUSION.
Subject Categories : Pharmacology
Distribution Statement : APPROVED FOR PUBLIC RELEASE